Search
Ganaxolone
go.drugbank.com/drugs/DB05087ApprovedInvestigationalGanaxolone is the 3β-methylated synthetic analog of [allopregnanolone],[L41130] a metabolite of [progesterone].[A3197] Ganaxolone belongs to a class of compounds referred to as neurosteroids. … [A245995] Ganaxolone, similar to its endogenous counterparts, is a positive allosteric modulator of GABA<sub>A</sub> receptors.
Methylnaltrexone
go.drugbank.com/drugs/DB06800ApprovedInvestigationalMethylnaltrexone is a pheriphally-acting μ-opioid antagonist that acts on the gastrointestinal tract to decrease opioid-induced constipation without producing analgesic effects or withdrawal symptoms. … FDA approved in 2008.
Categories: Heterocyclic Compounds with 4 or More RingsAlizapride
go.drugbank.com/drugs/DB01425InvestigationalThis kind of pharmacological activity makes it effective for use in the treatment of various kinds of nausea and vomiting, including that which may occur postoperatively. … Alizapride is a dopamine antagonist that is capable of demonstrating both prokinetic and antiemetic effects.
Categories: Dopamine D2 Receptor AntagonistsLiothyronine
go.drugbank.com/drugs/DB00279ApprovedInvestigationalVet approvedLiothyronine is the active form of thyroxine which is composed in a basic chemical structure by a tyrosine with bound iodine. … [T457] The exogenous liothyronine product was developed by King Pharmaceuticals and FDA approved in 1956.[L5578]
Categories: combinations of levothyroxine and liothyronineSynonyms: O-(4-hydroxy-3-iodophenyl)-3,5-diiodo-L-tyrosineRimegepant
go.drugbank.com/drugs/DB12457ApprovedInvestigationalprevention of migraines. … and cardiovascular disease due to their vasoconstrictive properties.
Thyrotropin alfa
go.drugbank.com/drugs/DB00024ApprovedInvestigationalVet approvedThe beta subunit (TSHB) bestows its receptor specificity due to the uniqueness to TSH. The amino acid sequence of thyrotropin alfa is identical to that of human pituitary thyroid stimulating hormone. … It is a heterodimeric glycoprotein comprised of two non-covalently linked subunits, an alpha subunit of 92 amino acid residues containing two N-linked glycosylation sites and a beta subunit of 112 residues
Escitalopram
go.drugbank.com/drugs/DB01175ApprovedInvestigationalthat the R-enantiomer of racemic citalopram actively dampens the activity of escitalopram rather than existing simply as an inactive enantiomer. … [A185726] Escitalopram also differentiates itself from other SSRIs via allosteric action on its target - this may be the mechanism responsible for its observed superior efficacy and faster onset compared
Categories: Combined Inhibitors of Serotonin/Norepinephrine Reuptake, Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeProducts: Escitalopram-GN 10 mg Filmtabletten, Escitalopram-GN 20 mg FilmtablettenPalbociclib
go.drugbank.com/drugs/DB09073ApprovedInvestigational[L5867] It was originally FDA approved on March 2015 for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer and its indications were updated in April 2019 to include male … It is a second generation cyclin-dependent kinase inhibitor[A176798] selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties.
Synonyms: 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one, 6-acetyl-8-cyclopentyl-5-methyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}pyrido[2,3-d]pyrimidin-7(8H)-oneBempedoic acid
go.drugbank.com/drugs/DB11936ApprovedInvestigationalA combination product of bempedoic acid and [ezetimibe] was approved on February 26, 2020 for increased control of LDL cholesterol levels in patients experiencing refractory elevations despite previous … [L12144,L12147] It was developed by Esperion Therapeutics Inc. and approved by the FDA on February 21, 2020.
Categories: Non-statin Hypolipidemic Agents Indicated for HyperlipidemiaLinvoseltamab
go.drugbank.com/drugs/DB17447ApprovedInvestigationalLinvoseltamab (INN), marketed as Lynozyfic™, is a bispecific human IgG4 monoclonal antibody developed by Regeneron that promotes the interaction of B-cell maturation antigen (BCMA) on multiple myeloma … relapsed or refractory multiple myeloma (RRMM).